Prior notification of a concentration

(Case M.10188 — Illumina/GRAIL)

(Text with EEA relevance)

(2021/C 248/05)

1. On 16 June 2021, the Commission received notification of a proposed concentration pursuant to Article 4 and following a referral pursuant to Article 22 of Council Regulation (EC) No 139/2004 ([1]).

This notification concerns the following undertakings:

— Illumina, Inc. ('Illumina', US),

— GRAIL, Inc. ('GRAIL', US)

Illumina acquires within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of GRAIL.

The concentration is accomplished by way of purchase of shares.

The concentration has been referred to the Commission by the French Autorité de la Concurrence pursuant to Article 22 (3) of the Merger Regulation. The referral was subsequently joined by Belgium, Greece, Iceland, the Netherlands and Norway.

2. The business activities of the undertakings concerned are:

— for Illumina: a global genomics company, which principally develops, manufactures and commercialises next generation sequencing ('NGS') systems for genetic and genomic analysis,

— for GRAIL: a healthcare company, which is focused on developing technologies for cancer detection tests based on NGS. GRAIL has also started initial, limited commercialisation of its Galleri test in the US.

3. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.10188 — Illumina/GRAIL

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

European Commission
Directorate-General for Competition
Merger Registry
1049 Bruxelles/Brussel
BELGIQUE/BELGIË

([1]) OJ L 24, 29.1.2004, p. 1 (the 'Merger Regulation').